- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
205
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
205 companies
Puma Biotechnology
Market Cap: US$170.8m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$3.37
7D
0.6%
1Y
-13.1%
Avalo Therapeutics
Market Cap: US$39.2m
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
AVTX
US$3.59
7D
-5.3%
1Y
-70.3%
Evaxion
Market Cap: US$14.9m
A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
EVAX
US$2.63
7D
52.0%
1Y
-85.3%
aTyr Pharma
Market Cap: US$344.4m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$4.20
7D
12.0%
1Y
150.0%
Citius Pharmaceuticals
Market Cap: US$7.3m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$0.70
7D
2.8%
1Y
-95.6%
Aldeyra Therapeutics
Market Cap: US$131.8m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$2.22
7D
-1.3%
1Y
-40.0%
Checkpoint Therapeutics
Market Cap: US$351.0m
A commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
CKPT
US$4.23
7D
1.3%
1Y
131.1%
InflaRx
Market Cap: US$123.3m
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
IFRX
US$0.73
7D
-56.8%
1Y
-50.0%
Sera Prognostics
Market Cap: US$63.3m
A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
SERA
US$1.65
7D
-14.1%
1Y
-82.8%
Cabaletta Bio
Market Cap: US$88.3m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$1.87
7D
4.2%
1Y
-81.4%
Protalix BioTherapeutics
Market Cap: US$124.2m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.59
7D
-7.0%
1Y
42.0%
Rocket Pharmaceuticals
Market Cap: US$251.0m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$2.48
7D
-62.4%
1Y
-88.0%
Mereo BioPharma Group
Market Cap: US$346.6m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$2.19
7D
-2.2%
1Y
-35.4%
CureVac
Market Cap: US$979.4m
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$4.44
7D
13.8%
1Y
17.2%
ImmunoPrecise Antibodies
Market Cap: US$24.4m
Operates as a techbio company.
IPA
US$0.56
7D
14.2%
1Y
-50.2%
Grace Therapeutics
Market Cap: US$40.5m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$2.88
7D
-1.3%
1Y
9.9%
Corvus Pharmaceuticals
Market Cap: US$283.0m
A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
CRVS
US$3.78
7D
4.1%
1Y
80.0%
Quantum-Si
Market Cap: US$352.3m
A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).
QSI
US$1.78
7D
20.7%
1Y
13.4%
Opus Genetics
Market Cap: US$46.4m
A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).
IRD
US$1.01
7D
-1.5%
1Y
-41.1%
Connect Biopharma Holdings
Market Cap: US$41.6m
A clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases.
CNTB
US$0.78
7D
-4.3%
1Y
-51.3%
Unicycive Therapeutics
Market Cap: US$71.3m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$0.61
7D
7.2%
1Y
-27.3%
Ardelyx
Market Cap: US$949.8m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.91
7D
-2.0%
1Y
-40.8%
Acrivon Therapeutics
Market Cap: US$34.5m
A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
ACRV
US$1.10
7D
-4.3%
1Y
-85.3%
Nautilus Biotechnology
Market Cap: US$97.5m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
NAUT
US$0.74
7D
-5.4%
1Y
-71.2%
Genelux
Market Cap: US$94.7m
A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
GNLX
US$2.45
7D
-1.6%
1Y
-12.5%
Savara
Market Cap: US$408.7m
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$2.14
7D
-26.6%
1Y
-48.6%
Xenetic Biosciences
Market Cap: US$4.4m
A biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
XBIO
US$2.90
7D
-5.5%
1Y
-23.1%
Whitehawk Therapeutics
Market Cap: US$84.2m
An oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
WHWK
US$1.74
7D
-9.6%
1Y
-1.1%
Amylyx Pharmaceuticals
Market Cap: US$420.7m
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$4.79
7D
-11.8%
1Y
186.8%
4D Molecular Therapeutics
Market Cap: US$158.4m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$3.47
7D
-2.3%
1Y
-85.5%
Vanda Pharmaceuticals
Market Cap: US$255.2m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.31
7D
-0.2%
1Y
-12.4%
Olema Pharmaceuticals
Market Cap: US$352.4m
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
OLMA
US$4.96
7D
-1.0%
1Y
-48.6%
PharmaCyte Biotech
Market Cap: US$6.9m
A biotechnology company, develops and commercializes cellular therapies for cancer in the United States.
PMCB
US$1.07
7D
2.7%
1Y
-46.0%
Sagimet Biosciences
Market Cap: US$108.2m
A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
SGMT
US$3.40
7D
5.6%
1Y
-37.8%
RenovoRx
Market Cap: US$45.3m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.30
7D
6.1%
1Y
5.3%
Xilio Therapeutics
Market Cap: US$45.5m
A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
XLO
US$0.94
7D
12.2%
1Y
0.1%